A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 18 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Budigalimab (Primary) ; Livmoniplimab (Primary) ; Atezolizumab; Bevacizumab; Durvalumab; Tremelimumab
Indications Carcinoma; Liver cancer
Focus Therapeutic Use
Acronyms LIVIGNO-2
Sponsors AbbVie

Most Recent Events

12 Dec 2024 Planned End Date changed from 6 Sep 2030 to 1 Sep 2030.
12 Dec 2024 Planned primary completion date changed from 6 Sep 2030 to 1 Sep 2030.
29 May 2024 Trial design discussed at 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight